• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Xoma Corp 8.625% (NQ: XOMAP )

    25.17 -0.15 (-0.59%)
    Streaming Delayed Price Updated: 11:25 AM EDT, Jul 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,071
    Open 25.33
    Bid (Size) 25.13 (1)
    Ask (Size) 25.60 (2)
    Prev. Close 25.32
    Today's Range 25.13 - 25.33
    52wk Range 21.40 - 26.48
    Shares Outstanding N/A
    Dividend Yield 8.57%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    XOMA Declares Quarterly Preferred Stock Dividends
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
    From XOMA Corporation
    Via GlobeNewswire

    Performance

    YTD
    -2.25%
    -2.25%
    1 Month
    -3.21%
    -3.21%
    3 Month
    +0.44%
    +0.44%
    6 Month
    -0.28%
    -0.28%
    1 Year
    +3.16%
    +3.16%

    More News

    Read More
    XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Corporation Announces Closing of Tender Offer
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Declares Quarterly Preferred Stock Dividends
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
    From XOMA Corporation
    Via GlobeNewswire
    XOMA to Present at Upcoming Investor Conferences in March
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
    From XOMA Corporation
    Via GlobeNewswire
    FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Announces Stock Repurchase Program of up to $50 Million
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Declares Quarterly Preferred Stock Dividends
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Declares Quarterly Preferred Stock Dividends
    From XOMA Corporation
    Via GlobeNewswire
    XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Added to the Russell 2000® and Russell 3000® Indexes
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset
    From XOMA Corporation
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.